



Modus Therapeutics strengthens its board

STOCKHOLM – 19 November, 2015. Modus Therapeutics, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces Jim Van heusden has been elected as a new member of the board.

Jim Van heusden is CEO of Karolinska Development, having joined in March 2015. He has more than 20 years' experience within venture capital, drug discovery and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills (2013-2015) and as Partner at the European investment company Gimv (2001-2013). During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom (as Chairman), Ablynx, ActoGeniX, Pronota and Prosensa. During 1993-2001, he worked as Senior Scientist at Janssen Pharmaceuticals (Johnson & Johnson).

He holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp and a PhD in molecular and cellular biology from the University of Maastricht.

“We are pleased to welcome Jim Van heusden to the Modus Therapeutics board, as he brings with him his years of experience in the life science industry, together with unique entrepreneurial skills,” said Modus Therapeutics CEO Christina Herder.

For further information, please contact:

Christina Herder, CEO:

Tel: +46 70 374 71 56

E-mail: christina.herder@modustx.com

David Dible/ Pip Batty, Citigate Dewe Rogerson

Tel: +44 20 7638 9571

E-mail: david.dible@citigatedr.co.uk

About Modus Therapeutics AB

Modus Therapeutics is a Swedish biotech company developing sevuparin - a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients' red blood cells form a sickled shape, making blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients' blood flow, thereby reducing their pain as well as the amount of time they will need to spend in hospital. Modus Therapeutics plans to develop a presentation of sevuparin that the patient can self-administer allowing them to live a more normal life by terminating early the painful episodes that result in them being hospitalised.

Modus Therapeutics is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.modustx.com



About Sevuparin

Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions, caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life. Modus Therapeutics is currently enrolling patients in a Phase II study with the aim to present data during second half of 2016.